1 minute read

Newsom: California will not do business with Walgreens

Gov. Gavin Newsom (D-Calif.) announced on Monday that California will not do business with Walgreens following the company’s announcement of its decision on Friday to not distribute the abortion pill mifepristone in 20 states.

The move comes amid pressure from conservative lawmakers and threats of legal action against Walgreens and CVS from 20 Republican state attorneys general, who claimed in a Feb. 1 press release that selling mifepristone is “unsafe and illegal.”

Mifepristone is still legal in several of the states where Walgreens has decided to stop providing it in response to the scepter of lawsuits from state attorneys general: Alaska, Iowa, Kansas and Montana.

Newsom’s office told NPR that California will review “all relationships between Walgreens and the state,” but declined to provide more specifics.

“California won’t be doing business with @walgreens – or any company that cowers to the extremists and puts women’s lives at risk,” Newsom wrote in the tweet. “We’re done.”

“Elected officials targeting pharmacies and their ability to provide women with access to safe, effective, and FDA-approved medication is dangerous and just unacceptable,” White House Press Secretary Karine Jean-Pierre said during a briefing on March 3.

“The administration will continue to stand by the FDA’s expert judgment in approving and regulating medications. And in the face of barriers to access and concerns about safety of patients, healthcare providers, and pharmacists, we will continue to support access to this critical medication within the limits of the law,” Jean-Pierre said.

Meanwhile, Judge Matthew Kacsmaryk of the U.S. District Court for the Northern District of Texas is expected to soon rule on a case challenging the safety of mifepristone that advocates for reproductive justice fear could lead to a nationwide injunction prohibiting the sale and distribution of the abortion drug.

Medical experts have slammed the Texas plaintiffs’ lawsuit, arguing that Mifepristone’s safety and efficacy have been well demonstrated for years. Kacsmaryk, who was appointed by former President Donald Trump, is nevertheless expected to rule in their favor.

“The plaintiffs who have no legitimate standing have handpicked him to hear this case that has no merit because they know what they’re getting with Judge Kacsmaryk,” Sen. Ron Wyden (D-Ore.) said last month.

Jean-Pierre addressed the case during a press briefing on March 1: “The decision would be unprecedented, as you know, and devastating to women’s health. And we may find ourselves in uncharted territory,” she said.

“And so, we’re closely — closely working with the Justice Department and DHS — HHS on this, on how to be prepared for any range of outcome or potential outcomes,” Jean-Pierre added.

This article is from: